Prevention of meningococcal disease

Current use of polysaccharide and conjugate vaccines

Gregory A. Poland

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Invasive meningococcal disease (IMD), although uncommon, is difficult to diagnose and can be rapidly fatal, even in healthy young persons. IMD is cyclic, and serogroups responsible for disease vary by age group, although the prevalence of the serogroups changes over time and by geographical location. Two quadrivalent vaccines are licensed in the United States to prevent IMD caused by serogroups A, C, Y, and W-135, and the US Centers for Disease Control and Prevention recommends routine vaccination with quadrivalent meningococcal conjugate vaccine of adolescents 11-18 years of age and vaccination of persons 2-55 years of age who are at elevated risk of IMD. Efforts to prevent IMD remain challenging, because there is neither an immunogenic vaccine for infants nor a vaccine to prevent serogroup B disease that is currently licensed. Obstacles to achieving optimal vaccine coverage among adolescents persist, and strategies are needed to address these shortcomings.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume50
Issue numberSUPPL. 2
DOIs
StatePublished - Mar 1 2010

Fingerprint

Conjugate Vaccines
Polysaccharides
Vaccines
Vaccination
Meningococcal Vaccines
Centers for Disease Control and Prevention (U.S.)
Age Groups
Serogroup

ASJC Scopus subject areas

  • Medicine(all)
  • Infectious Diseases
  • Microbiology (medical)

Cite this

Prevention of meningococcal disease : Current use of polysaccharide and conjugate vaccines. / Poland, Gregory A.

In: Clinical Infectious Diseases, Vol. 50, No. SUPPL. 2, 01.03.2010.

Research output: Contribution to journalArticle

@article{e4eecd358cfa47edbb3c2050539b3b49,
title = "Prevention of meningococcal disease: Current use of polysaccharide and conjugate vaccines",
abstract = "Invasive meningococcal disease (IMD), although uncommon, is difficult to diagnose and can be rapidly fatal, even in healthy young persons. IMD is cyclic, and serogroups responsible for disease vary by age group, although the prevalence of the serogroups changes over time and by geographical location. Two quadrivalent vaccines are licensed in the United States to prevent IMD caused by serogroups A, C, Y, and W-135, and the US Centers for Disease Control and Prevention recommends routine vaccination with quadrivalent meningococcal conjugate vaccine of adolescents 11-18 years of age and vaccination of persons 2-55 years of age who are at elevated risk of IMD. Efforts to prevent IMD remain challenging, because there is neither an immunogenic vaccine for infants nor a vaccine to prevent serogroup B disease that is currently licensed. Obstacles to achieving optimal vaccine coverage among adolescents persist, and strategies are needed to address these shortcomings.",
author = "Poland, {Gregory A.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1086/648964",
language = "English (US)",
volume = "50",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Prevention of meningococcal disease

T2 - Current use of polysaccharide and conjugate vaccines

AU - Poland, Gregory A.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Invasive meningococcal disease (IMD), although uncommon, is difficult to diagnose and can be rapidly fatal, even in healthy young persons. IMD is cyclic, and serogroups responsible for disease vary by age group, although the prevalence of the serogroups changes over time and by geographical location. Two quadrivalent vaccines are licensed in the United States to prevent IMD caused by serogroups A, C, Y, and W-135, and the US Centers for Disease Control and Prevention recommends routine vaccination with quadrivalent meningococcal conjugate vaccine of adolescents 11-18 years of age and vaccination of persons 2-55 years of age who are at elevated risk of IMD. Efforts to prevent IMD remain challenging, because there is neither an immunogenic vaccine for infants nor a vaccine to prevent serogroup B disease that is currently licensed. Obstacles to achieving optimal vaccine coverage among adolescents persist, and strategies are needed to address these shortcomings.

AB - Invasive meningococcal disease (IMD), although uncommon, is difficult to diagnose and can be rapidly fatal, even in healthy young persons. IMD is cyclic, and serogroups responsible for disease vary by age group, although the prevalence of the serogroups changes over time and by geographical location. Two quadrivalent vaccines are licensed in the United States to prevent IMD caused by serogroups A, C, Y, and W-135, and the US Centers for Disease Control and Prevention recommends routine vaccination with quadrivalent meningococcal conjugate vaccine of adolescents 11-18 years of age and vaccination of persons 2-55 years of age who are at elevated risk of IMD. Efforts to prevent IMD remain challenging, because there is neither an immunogenic vaccine for infants nor a vaccine to prevent serogroup B disease that is currently licensed. Obstacles to achieving optimal vaccine coverage among adolescents persist, and strategies are needed to address these shortcomings.

UR - http://www.scopus.com/inward/record.url?scp=77951650463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951650463&partnerID=8YFLogxK

U2 - 10.1086/648964

DO - 10.1086/648964

M3 - Article

VL - 50

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 2

ER -